A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies
- PMID: 30342844
- DOI: 10.1016/j.eururo.2018.10.012
A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies
Abstract
Background: Available models for predicting lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) might not be applicable to men diagnosed via magnetic resonance imaging (MRI)-targeted biopsies.
Objective: To assess the accuracy of available tools to predict LNI and to develop a novel model for men diagnosed via MRI-targeted biopsies.
Design, setting, and participants: A total of 497 patients diagnosed via MRI-targeted biopsies and treated with RP and extended pelvic lymph node dissection (ePLND) at five institutions were retrospectively identified.
Outcome measurements and statistical analyses: Three available models predicting LNI were evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analyses. A nomogram predicting LNI was developed and internally validated.
Results and limitations: Overall, 62 patients (12.5%) had LNI. The median number of nodes removed was 15. The AUC for the Briganti 2012, Briganti 2017, and MSKCC nomograms was 82%, 82%, and 81%, respectively, and their calibration characteristics were suboptimal. A model including PSA, clinical stage and maximum diameter of the index lesion on multiparametric MRI (mpMRI), grade group on targeted biopsy, and the presence of clinically significant PCa on concomitant systematic biopsy had an AUC of 86% and represented the basis for a coefficient-based nomogram. This tool exhibited a higher AUC and higher net benefit compared to available models developed using standard biopsies. Using a cutoff of 7%, 244 ePLNDs (57%) would be spared and a lower number of LNIs would be missed compared to available nomograms (1.6% vs 4.6% vs 4.5% vs 4.2% for the new nomogram vs Briganti 2012 vs Briganti 2017 vs MSKCC).
Conclusions: Available models predicting LNI are characterized by suboptimal accuracy and clinical net benefit for patients diagnosed via MRI-targeted biopsies. A novel nomogram including mpMRI and MRI-targeted biopsy data should be used to identify candidates for ePLND in this setting.
Patient summary: We developed the first nomogram to predict lymph node invasion (LNI) in prostate cancer patients diagnosed via magnetic resonance imaging-targeted biopsy undergoing radical prostatectomy. Adoption of this model to identify candidates for extended pelvic lymph node dissection could avoid up to 60% of these procedures at the cost of missing only 1.6% patients with LNI.
Keywords: Lymph node invasion; Magnetic resonance imaging-targeted biopsy; Nomogram; Pelvic lymph node dissection; Prostate cancer; Radical prostatectomy.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection.Eur Urol. 2020 Aug;78(2):138-142. doi: 10.1016/j.eururo.2020.03.023. Epub 2020 Apr 5. Eur Urol. 2020. PMID: 32268944
-
Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.Eur Urol. 2017 Oct;72(4):632-640. doi: 10.1016/j.eururo.2017.03.049. Epub 2017 Apr 12. Eur Urol. 2017. PMID: 28412062
-
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool.Eur Urol Oncol. 2023 Dec;6(6):543-552. doi: 10.1016/j.euo.2023.05.003. Epub 2023 Jun 1. Eur Urol Oncol. 2023. PMID: 37270378
-
Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches.Urologia. 2017 Feb 3;84(1):9-19. doi: 10.5301/uro.5000139. Epub 2015 Dec 16. Urologia. 2017. PMID: 26689534 Review.
-
Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis.Scand J Urol. 2017 Oct;51(5):345-350. doi: 10.1080/21681805.2017.1332680. Epub 2017 Jun 23. Scand J Urol. 2017. PMID: 28644701
Cited by
-
Comparison of Multiparametric MRI, [68Ga]Ga-PSMA-11 PET-CT, and Clinical Nomograms for Primary T and N Staging of Intermediate-to-High-Risk Prostate Cancer.Cancers (Basel). 2023 Dec 14;15(24):5838. doi: 10.3390/cancers15245838. Cancers (Basel). 2023. PMID: 38136382 Free PMC article.
-
A Nomogram for Predicting Prostate Cancer with Lymph Node Involvement in Robot-Assisted Radical Prostatectomy Era: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group).Diagnostics (Basel). 2022 Oct 20;12(10):2545. doi: 10.3390/diagnostics12102545. Diagnostics (Basel). 2022. PMID: 36292234 Free PMC article.
-
Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.Int Urol Nephrol. 2022 Mar;54(3):541-550. doi: 10.1007/s11255-022-03103-w. Epub 2022 Jan 19. Int Urol Nephrol. 2022. PMID: 35044553 Free PMC article.
-
Sentinel Lymph Node Biopsy in Prostate Cancer: An Overview of Diagnostic Performance, Oncological Outcomes, Safety, and Feasibility.Diagnostics (Basel). 2023 Jul 31;13(15):2543. doi: 10.3390/diagnostics13152543. Diagnostics (Basel). 2023. PMID: 37568905 Free PMC article. Review.
-
Preoperative prediction of pelvic lymph nodes metastasis in prostate cancer using an ADC-based radiomics model: comparison with clinical nomograms and PI-RADS assessment.Abdom Radiol (NY). 2022 Sep;47(9):3327-3337. doi: 10.1007/s00261-022-03583-5. Epub 2022 Jun 28. Abdom Radiol (NY). 2022. PMID: 35763053
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous